Phase i dose-escalation study of LCL161, an oral inhibitorof apoptosis proteins inhibitor, in patients with advanced solid tumors

Jeffrey R. Infante, E. Claire Dees, Anthony J. Olszanski, Shyeilla V. Dhuria, Suman Sen, Scott Cameron, Roger B. Cohen

Research output: Contribution to journalArticlepeer-review

156 Scopus citations

Fingerprint

Dive into the research topics of 'Phase i dose-escalation study of LCL161, an oral inhibitorof apoptosis proteins inhibitor, in patients with advanced solid tumors'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science